Have healthy

Mitigate more risks with the world’s most advanced whole genome screening for embryos
Make an informed Decision

Screen for more diseases with whole genome analysis

Detect genetic errors linked to severe diseases before pregnancy begins. Mitigate risks that could affect a future baby.
The difference is more data
Orchid sequences over 99%* of an embryo’s DNA, while alternatives sequence less than 1%.  With much more data, more risks can be identified.

What we screen for

Use whole genome data to identify monogenic and polygenic diseases. Alternatives miss detecting risks because they do not sequence the whole genome.
Monogenic screening

Get whole genome embryo screening

Make an informed decision with more data

Find the embryo at lowest risk for a disease that runs in your family

Estimate how much chronic disease risk can be mitigated
What People Are Saying
“This is the way to reduce disease and suffering in kids, and is the best thing you can do for your child and yourself. The fact that we have screened for so much gives us peace of mind. Understanding our genetics is a huge advantage.”
Rohan & Jen
Orchid customers
What People Are Saying
“Orchid gave us clarity around the things that we care about, especially our family history 
of conditions. We move forward now with so much more confidence than we would have.”
Kevin & Julia
Orchid customers
What People Are Saying
“We deeply believe in leveraging technology to better our lives. Orchid's groundbreaking technology was a game-changer for us. It provided invaluable insights as we embarked on the path to parenthood.”
Michelle & Tom
Orchid customers
What People Are Saying
We screened our embryos because were at risk for a hereditary cancer. Orchid found something more - we were carriers for the same condition. Without screening, 25% of our children could have the disease. Now, our kids are more likely to be healthy.
Andy & Ella
Orchid customers
What People Are Saying
“When we learned that PGT-WGS was an option we were  onboard. Orchid let us screen our embryos for a range of inherited diseases.  It's exciting that this technology is empowering parents to make informed choices.”
Roshan & Julie
Orchid customers

Get whole genome embryo screening

Make an informed decision with more data
How it works

Get the most extensive reports for your embryos

Your IVF doctor orders Orchid on your behalf. An embryologist sends Orchid’s lab ~5 cells from each embryo, the same amount of material required for standard testing.
Our team of experts reviews the genetic data and reports on the information requested for each embryo in your cycle.
Expert review
Meet with a board certified genetic counselor to explain the findings from the report, discuss specific risks related to each embryo tested, and answer any questions.

Ready to get started? Speak with a board certified genetic counselor.

Get access
Analyze more data + mitigate more risks

Detect more risks

Whole genome screening mitigates risk for many genetic diseases other tests miss. Orchid combines all the results from PGT-A, PGT-M, and PGT-P and more in a single report.
Detect extra or missing chromosomes
Detect one gene that causes one condition
Detect genetic predispositions (genetic risk scores)
Detect neurodevelopmental disorders (monogenic)
Detect pediatric and adult onset cancers (monogenic)
Detect birth defects (monogenic)
Our advisors

Built by world class experts

Designed and vetted by our team of leading experts in reproductive medicine, embryology, and genetics.
Jacques Cohen, PhD
Pioneering Embryologist and foundational figure in IVF and ART innovation
Jerry Lanchbury, PhD
Expert in immunogenetics, 100+ peer reviewed publications
Barry Behr, PhD
Professor of Obstetrics and Gynecology Emeritus at the Stanford Medical Center

More questions? Read more about the science behind Orchid.

Learn More


George Church
Professor of Genetics at Harvard Medical School and MIT
Elad Gil
Entrepreneur and Investor, Co-Founder of Color Genomics
Vitalik Buterin
Co-Founder of Ethereum
Anne Wojcicki
Co-Founder & CEO, 23andMe
Carlos Bustamante
MacArthur Award Winning Geneticist
Brian Armstrong
CEO of Coinbase, Co-Founder of NewLimit

Make an informed decision

Get whole genome information for your embryos
* Percentage is based on validation studies using genomic regions of National Institute of Standards and Technology GIAB samples